Deals3 Oct 2025, 02:29 pm
Panacea Biotec Secures US$ 35.65 Million Contract from Unicef for bOPV Supply
AI Summary
Panacea Biotec Ltd has been awarded a Long-Term Agreement by Unicef for the supply of bivalent oral polio vaccine (bOPV) worth approximately US$ 35.65 million (~Rs.315 Crore) starting from 1st April 2026 to 31st March 2030. The agreement is for the supply of bOPV in 10 and 20 vial presentations for Q2 CY2026 and CY2027.
Key Highlights
- Awarded a Long-Term Agreement by Unicef for bOPV supply
- Worth approximately US$ 35.65 million
- Supply to continue from 1st April 2026 to 31st March 2030
- Supply of bOPV in 10 and 20 vial presentations for Q2 CY2026 and CY2027
- Agreement in line with Regulation 30 of the SEBI LODR Regulations